SPN-821 not checked
Supernus Pharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling”In the company’s words, NCT07226661 on ClinicalTrials.gov
- Tested for
- Major Depressive Disorder (MDD)
- Main trialPhase 2
- “This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder”In the company’s words, NCT07226661 on ClinicalTrials.gov
Other drugs for Major Depressive Disorder (MDD)
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2026 | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026